Safety and Efficacy of Treg Cell in the Treatment of GVHD

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

May 31, 2027

Conditions
GVHD
Interventions
DRUG

Regulator T Cells

Autologous Regulatory T-Lymphocytes 1\*10\^6/kg, 2\*10\^6/kg, 4\*10\^6/kg and 8\*10\^6/kg, respectively until restrictive toxic reaction occurs

All Listed Sponsors
lead

Xuzhou Medical University

OTHER

NCT06411184 - Safety and Efficacy of Treg Cell in the Treatment of GVHD | Biotech Hunter | Biotech Hunter